Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without regular ...
Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been ...
It's a good idea to go against the current market sentiment on this one. Vertex Pharmaceuticals continues to generate most of its revenue from its cystic fibrosis (CF) franchise. The company's ...
Vertex Pharmaceuticals recently presented updated interim data at the 2025 ASN Kidney Week, revealing significant proteinuria reductions and eGFR stabilization with povetacicept in patients with IgA ...
News headlines Vertex Pharmaceuticals (VRTX) is experiencing notable momentum with revised analyst estimates and a focus on its expanding pipeline. Recent performance has shown a 9.2% increase over ...
MusicRadar on MSN
Kenny Wayne Shepherd on covering Hendrix, his fistful of Dumbles and the secret to great overdrive
Kenny Wayne Shepherd is one of the great connoisseurs of electric guitar tone. Over the years he has refined his tastes to ...
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 p.m. to 4 a.m. ET, Sunday through Thursday, when regular markets are closed. Chart does not reflect ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback